Liberty One Investment Management LLC Makes New $261,000 Investment in Axon Enterprise, Inc (NASDAQ:AXON)

Liberty One Investment Management LLC acquired a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 496 shares of the biotechnology company's stock, valued at approximately $261,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in Axon Enterprise during the 1st quarter valued at about $1,110,000. CX Institutional acquired a new position in Axon Enterprise during the 1st quarter valued at about $115,000. GAMMA Investing LLC increased its holdings in shares of Axon Enterprise by 11.8% in the first quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company's stock valued at $765,000 after purchasing an additional 154 shares during the period. DAVENPORT & Co LLC increased its holdings in shares of Axon Enterprise by 5.1% in the first quarter. DAVENPORT & Co LLC now owns 940 shares of the biotechnology company's stock valued at $494,000 after purchasing an additional 46 shares during the period. Finally, Blue Trust Inc. increased its holdings in shares of Axon Enterprise by 33.1% in the first quarter. Blue Trust Inc. now owns 169 shares of the biotechnology company's stock valued at $89,000 after purchasing an additional 42 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Brittany Bagley sold 3,400 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total value of $2,380,000.00. Following the transaction, the chief financial officer owned 131,833 shares in the company, valued at $92,283,100. This trade represents a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CRO Cameron Brooks sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $740.76, for a total value of $2,222,280.00. Following the completion of the transaction, the executive owned 19,447 shares in the company, valued at approximately $14,405,559.72. This trade represents a 13.36% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,642 shares of company stock valued at $30,500,428. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Price Performance

AXON stock traded down $3.37 during mid-day trading on Friday, reaching $729.62. 1,120,957 shares of the company's stock were exchanged, compared to its average volume of 545,551. The company has a market cap of $56.80 billion, a price-to-earnings ratio of 176.24, a price-to-earnings-growth ratio of 83.99 and a beta of 1.29. The stock's 50 day moving average is $752.67 and its 200 day moving average is $641.02. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. Axon Enterprise, Inc has a 12-month low of $279.02 and a 12-month high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The business's quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 earnings per share. On average, research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wolfe Research assumed coverage on Axon Enterprise in a report on Monday, July 7th. They issued an "outperform" rating on the stock. The Goldman Sachs Group increased their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Bank of America increased their price objective on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Barclays increased their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, Needham & Company LLC increased their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and an average target price of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.